Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.
2.

Clear cell renal cell carcinoma with Paneth-like cells: Clinicopathologic, morphologic, immunohistochemical, ultrastructural, and molecular analysis of 13 cases.

Kojima F, Bulimbasic S, Alaghehbandan R, Martinek P, Vanecek T, Michalova K, Pivovarcikova K, Michal M, Hora M, Murata SI, Sugawara E, Rogala J, Limani R, Hes O.

Ann Diagn Pathol. 2019 Jun 3;41:96-101. doi: 10.1016/j.anndiagpath.2019.05.012. [Epub ahead of print]

PMID:
31202196
3.

Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.

Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH, Hofmann F, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A, Bensalah K.

Eur Urol Oncol. 2019 Jun 3. pii: S2588-9311(19)30054-9. doi: 10.1016/j.euo.2019.04.005. [Epub ahead of print] Review.

PMID:
31171501
4.

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.

Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB, Ljungberg B, Marconi L, Merseburger AS, Volpe A, Abu-Ghanem Y, Dabestani S, Fernández-Pello S, Hofmann F, Kuusk T, Tahbaz R, Bex A.

Eur Urol. 2019 Aug;76(2):151-156. doi: 10.1016/j.eururo.2019.05.022.

PMID:
31151678
5.

Primary renal well-differentiated neuroendocrine tumour (carcinoid): next-generation sequencing study of 11 cases.

Pivovarcikova K, Agaimy A, Martinek P, Alaghehbandan R, Perez-Montiel D, Alvarado-Cabrero I, Rogala J, Kuroda N, Rychly B, Gasparov S, Michalova K, Michal M, Hora M, Pitra T, Tuckova I, Laciok S, Mareckova J, Hes O.

Histopathology. 2019 Jul;75(1):104-117. doi: 10.1111/his.13856.

PMID:
30851202
6.

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A.

Eur Urol. 2019 May;75(5):799-810. doi: 10.1016/j.eururo.2019.02.011. Epub 2019 Feb 23.

PMID:
30803729
7.

Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases.

Pivovarcikova K, Martinek P, Grossmann P, Trpkov K, Alaghehbandan R, Magi-Galluzzi C, Pane Foix M, Condom Mundo E, Berney D, Gill A, Rychly B, Michalova K, Rogala J, Pitra T, Micsik T, Polivka J, Hora M, Tanas Isikci O, Skalova S, Mareckova J, Michal M, Hes O.

Ann Diagn Pathol. 2019 Apr;39:63-68. doi: 10.1016/j.anndiagpath.2019.02.008. Epub 2019 Feb 10.

PMID:
30785029
8.

Efficacy of chest computed tomography prediction of the pathological TNM stage of thymic epithelial tumours.

White DB, Hora MJ, Jenkins SM, Marks RS, Garces YI, Cassivi SD, Roden AC.

Eur J Cardiothorac Surg. 2019 Feb 11. doi: 10.1093/ejcts/ezz013. [Epub ahead of print]

PMID:
30753469
9.

The decision to discontinue screening for carnitine uptake disorder in New Zealand.

Wilson C, Knoll D, de Hora M, Kyle C, Glamuzina E, Webster D.

J Inherit Metab Dis. 2019 Jan;42(1):86-92. doi: 10.1002/jimd.12030.

PMID:
30740730
10.

Imaging in Suspected Renal-Cell Carcinoma: Systematic Review.

Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Albiges L, Stewart F, Volpe A, Graser A, Schlemmer M, Yuan C, Lam T, Staehler M.

Clin Genitourin Cancer. 2019 Apr;17(2):e345-e355. doi: 10.1016/j.clgc.2018.07.024. Epub 2018 Aug 11.

PMID:
30528378
11.

Papillary pattern in clear cell renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 23 cases.

Alaghehbandan R, Ulamec M, Martinek P, Pivovarcikova K, Michalova K, Skenderi F, Hora M, Michal M, Hes O.

Ann Diagn Pathol. 2019 Feb;38:80-86. doi: 10.1016/j.anndiagpath.2018.11.004. Epub 2018 Nov 22.

PMID:
30502717
12.

Reactivity of CK7 across the spectrum of renal cell carcinomas with clear cells.

Gonzalez ML, Alaghehbandan R, Pivovarcikova K, Michalova K, Rogala J, Martinek P, Foix MP, Mundo EC, Comperat E, Ulamec M, Hora M, Michal M, Hes O.

Histopathology. 2019 Mar;74(4):608-617. doi: 10.1111/his.13791. Epub 2019 Jan 31.

PMID:
30444288
13.

The Antibody Light-Chain Linker Regulates Domain Orientation and Amyloidogenicity.

Weber B, Hora M, Kazman P, Göbl C, Camilloni C, Reif B, Buchner J.

J Mol Biol. 2018 Dec 7;430(24):4925-4940. doi: 10.1016/j.jmb.2018.10.024. Epub 2018 Nov 8.

PMID:
30414962
14.

Population specificity of sex estimation from vertebrae.

Hora M, Sládek V.

Forensic Sci Int. 2018 Oct;291:279.e1-279.e12. doi: 10.1016/j.forsciint.2018.08.015. Epub 2018 Aug 25.

PMID:
30236909
15.

"High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.

He H, Trpkov K, Martinek P, Isikci OT, Maggi-Galuzzi C, Alaghehbandan R, Gill AJ, Tretiakova M, Lopez JI, Williamson SR, Montiel DP, Sperga M, Comperat E, Brimo F, Yilmaz A, Pivovarcikova K, Michalova K, Slouka D, Prochazkova K, Hora M, Bonert M, Michal M, Hes O.

Virchows Arch. 2018 Dec;473(6):725-738. doi: 10.1007/s00428-018-2456-4. Epub 2018 Sep 19.

PMID:
30232607
16.

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Volpe A, Ljungberg B, Escudier B, Powles T.

Eur Urol. 2018 Dec;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029. Epub 2018 Sep 7. No abstract available.

PMID:
30201510
17.

Cystic Appearance on Imaging Methods (Bosniak III-IV) in Histologically Confirmed Papillary Renal Cell Carcinoma is Mainly Characteristic of Papillary Renal Cell Carcinoma Type 1 and Might Predict a Relatively Indolent Behavior of Papillary Renal Cell Carcinoma.

Procházková K, Mírka H, Trávníček I, Pitra T, Kolár J, Roušarová M, Hošek P, Bajcurová K, Ferda J, Staehler M, Brookman May SD, Hes O, Hora M.

Urol Int. 2018;101(4):409-416. doi: 10.1159/000492719. Epub 2018 Sep 10.

PMID:
30199877
18.

Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Staehler M, Volpe A, Powles T.

Eur Urol. 2018 Dec;74(6):805-809. doi: 10.1016/j.eururo.2018.08.008. Epub 2018 Aug 31.

PMID:
30177291
19.

Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.

Michalova K, Steiner P, Alaghehbandan R, Trpkov K, Martinek P, Grossmann P, Montiel DP, Sperga M, Straka L, Prochazkova K, Cempirkova D, Horava V, Bulimbasic S, Pivovarcikova K, Daum O, Ondic O, Rotterova P, Michal M, Hora M, Hes O.

Ann Diagn Pathol. 2018 Aug;35:1-6. doi: 10.1016/j.anndiagpath.2018.01.010. Epub 2018 Feb 3.

PMID:
30072012
20.

The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6-A Study on 320 Patients After Radical Prostatectomy.

Dolejsova O, Kucera R, Fuchsova R, Topolcan O, Svobodova H, Hes O, Eret V, Pecen L, Hora M.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818787377. doi: 10.1177/1533033818787377.

21.

Editorial Comment to Urological laparoendoscopic single-site and reduced port surgery: A nationwide survey in Japan.

Hora M.

Int J Urol. 2018 Mar;25(3):268-269. doi: 10.1111/iju.13546. Epub 2018 Feb 25. No abstract available.

22.

Physical basis of amyloid fibril polymorphism.

Close W, Neumann M, Schmidt A, Hora M, Annamalai K, Schmidt M, Reif B, Schmidt V, Grigorieff N, Fändrich M.

Nat Commun. 2018 Feb 16;9(1):699. doi: 10.1038/s41467-018-03164-5.

23.

Magnetic resonance imaging as an adjunct diagnostic tool in computed tomography defined Bosniak IIF-III renal cysts: a multicenter study.

Pitra T, Pivovarcikova K, Tupy R, Alaghehbandan R, Barakova T, Travnicek I, Prochazkova K, Klatte T, Chlosta P, Hes O, Hora M.

World J Urol. 2018 Jun;36(6):905-911. doi: 10.1007/s00345-018-2176-z. Epub 2018 Jan 30.

PMID:
29383479
25.

Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.

Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31001-1. doi: 10.1016/j.eururo.2017.11.016. [Epub ahead of print]

PMID:
29223605
26.

Low-grade spindle cell proliferation in clear cell renal cell carcinoma is unlikely to be an initial step in sarcomatoid differentiation.

Tanas Isikci O, He H, Grossmann P, Alaghehbandan R, Ulamec M, Michalova K, Pivovarcikova K, Montiel DP, Ondic O, Daum O, Prochazkova K, Hora M, Michal M, Hes O.

Histopathology. 2018 Apr;72(5):804-813. doi: 10.1111/his.13447. Epub 2018 Jan 31.

PMID:
29194709
27.

Renal Cell Carcinoma With Leiomyomatous Stroma: A Group of Tumors With Indistinguishable Histopathologic Features, But 2 Distinct Genetic Profiles: Next-Generation Sequencing Analysis of 6 Cases Negative for Aberrations Related to the VHL gene.

Petersson F, Martinek P, Vanecek T, Pivovarcikova K, Peckova K, Ondic O, Perez-Montiel D, Skenderi F, Ulamec M, Nenutil R, Hora M, Svoboda T, Rotterova P, Dusek M, Michal M, Hes O.

Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):192-197. doi: 10.1097/PAI.0000000000000410.

PMID:
29084058
28.

A practical guide and decision-making protocol for the management of complex renal cystic masses.

Weibl P, Hora M, Kollarik B, Kalusova K, Pitra T, Remzi M, Hübner W, Balzer P, Klatte T.

Arab J Urol. 2017 Mar 30;15(2):115-122. doi: 10.1016/j.aju.2017.02.001. eCollection 2017 Jun.

29.

High-grade renal cell carcinoma with emperipolesis: Clinicopathological, immunohistochemical and molecular-genetic analysis of 14 cases.

Rotterova P, Martinek P, Alaghehbandan R, Prochazkova K, Damjanov I, Rogala J, Suster S, Perez-Montiel D, Alvarado-Cabrero I, Sperga M, Svajdler M, Michalova K, Pivovarcikova K, Daum O, Hora M, Dusek M, Ondic O, Stehlikova A, Michal M, Hes O.

Histol Histopathol. 2018 Mar;33(3):277-287. doi: 10.14670/HH-11-925. Epub 2017 Sep 1.

PMID:
28861890
30.

Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients.

Borgmann H, Musquera M, Haferkamp A, Vilaseca A, Klatte T, Shariat SF, Scavuzzo A, Jimenez Rios MA, Wolff I, Capitanio U, Dell'Oglio P, Krabbe LM, Herrmann E, Ecke T, Vergho D, Huck N, Wagener N, Pahernik S, Zastrow S, Wirth M, Surcel C, Mirvald C, Prochazkova K, Hutterer G, Zigeuner R, Cindolo L, Hora M, Stief CG, May M, Brookman-May SD.

World J Urol. 2017 Dec;35(12):1891-1897. doi: 10.1007/s00345-017-2078-5. Epub 2017 Aug 23.

PMID:
28836063
31.

Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.

Alaghehbandan R, Stehlik J, Trpkov K, Magi-Galluzzi C, Condom Mundo E, Pane Foix M, Berney D, Sibony M, Suster S, Agaimy A, Montiel DP, Pivovarcikova K, Michalova K, Daum O, Ondic O, Rotterova P, Dusek M, Hora M, Michal M, Hes O.

Ann Diagn Pathol. 2017 Aug;29:17-22. doi: 10.1016/j.anndiagpath.2017.04.007. Epub 2017 Apr 24.

PMID:
28807336
32.

MAK33 antibody light chain amyloid fibrils are similar to oligomeric precursors.

Hora M, Sarkar R, Morris V, Xue K, Prade E, Harding E, Buchner J, Reif B.

PLoS One. 2017 Jul 26;12(7):e0181799. doi: 10.1371/journal.pone.0181799. eCollection 2017.

33.

A virtual clinical trial using projection-based nodule insertion to determine radiologist reader performance in lung cancer screening CT.

Yu L, Hu Q, Koo CW, Takahashi EA, Levin DL, Johnson TF, Hora MJ, Dirks S, Chen B, McMillan K, Leng S, Fletcher JG, McCollough CH.

Proc SPIE Int Soc Opt Eng. 2017 Feb 11;10132. pii: 101321R. doi: 10.1117/12.2255593. Epub 2017 Mar 9.

34.

Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases.

Skenderi F, Ulamec M, Vanecek T, Martinek P, Alaghehbandan R, Foix MP, Babankova I, Montiel DP, Alvarado-Cabrero I, Svajdler M, Dubinský P, Cempirkova D, Pavlovsky M, Vranic S, Daum O, Ondic O, Pivovarcikova K, Michalova K, Hora M, Rotterova P, Stehlikova A, Dusek M, Michal M, Hes O.

Ann Diagn Pathol. 2017 Apr;27:48-56. doi: 10.1016/j.anndiagpath.2017.01.005. Epub 2017 Jan 19.

PMID:
28325361
35.

Body size and lower limb posture during walking in humans.

Hora M, Soumar L, Pontzer H, Sládek V.

PLoS One. 2017 Feb 13;12(2):e0172112. doi: 10.1371/journal.pone.0172112. eCollection 2017.

36.

Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains.

Hora M, Carballo-Pacheco M, Weber B, Morris VK, Wittkopf A, Buchner J, Strodel B, Reif B.

Sci Rep. 2017 Jan 27;7:41515. doi: 10.1038/srep41515.

37.

Surgical treatment of kidney tumors - contemporary trends in clinical practice.

Hora M, Eret V, Trávníček I, Procházková K, Pitra T, Dolejšová O, Hes O, Petersson F.

Cent European J Urol. 2016;69(4):341-346. doi: 10.5173/ceju.2016.845. Epub 2016 Sep 22.

38.

Urological procedures in Central Europe and the current reality based on the national registries of Czech Republic, Hungary, and Poland (2012 status).

Adamczyk P, Juszczak K, Drewa T, Hora M, Nyirády P, Sosnowski M.

Cent European J Urol. 2016;69(4):327-333. doi: 10.5173/ceju.2016.886. Epub 2016 Nov 30.

39.

Cystic and necrotic papillary renal cell carcinoma: prognosis, morphology, immunohistochemical, and molecular-genetic profile of 10 cases.

Peckova K, Martinek P, Pivovarcikova K, Vanecek T, Alaghehbandan R, Prochazkova K, Montiel DP, Hora M, Skenderi F, Ulamec M, Rotterova P, Daum O, Ferda J, Davidson W, Ondic O, Dubova M, Michal M, Hes O.

Ann Diagn Pathol. 2017 Feb;26:23-30. doi: 10.1016/j.anndiagpath.2016.10.007. Epub 2016 Oct 20.

PMID:
28038707
40.

Solid- and solution-state nuclear magnetic resonance spectroscopic studies on antibody light chain amyloid formation and interactions with epigallocatechin gallate.

Hora M, Carballo Pacheco M, Weber B, Buchner J, Strodel B, Reif B.

Amyloid. 2017 Mar;24(sup1):10. doi: 10.1080/13506129.2016.1269736. Epub 2016 Dec 26. No abstract available.

PMID:
28019720
41.

Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Staehler M, Volpe A, Powles T.

Eur Urol. 2017 May;71(5):719-722. doi: 10.1016/j.eururo.2016.11.034. Epub 2016 Dec 13.

PMID:
27986369
42.

A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.

Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2017 Mar;71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. Epub 2016 Dec 8. Review.

PMID:
27939075
43.

The Risk of Fatty Acid Oxidation Disorders and Organic Acidemias in Children with Normal Newborn Screening.

Wilson C, Knoll D, de Hora M, Kyle C, Glamuzina E, Webster D.

JIMD Rep. 2017;35:53-58. doi: 10.1007/8904_2016_25. Epub 2016 Dec 8.

44.

Evaluation of the revised New Zealand national newborn screening protocol for congenital hypothyroidism.

Heather NL, Hofman PL, de Hora M, Carll J, Derraik JG, Webster D.

Clin Endocrinol (Oxf). 2017 Mar;86(3):431-437. doi: 10.1111/cen.13250. Epub 2016 Oct 21.

PMID:
27696498
45.

Morphological Characterization of Papillary Renal Cell Carcinoma Type 1, the Efficiency of Its Surgical Treatment.

Procházková K, Staehler M, Trávníček I, Pitra T, Eret V, Ürge T, Eberlová L, Roušarová M, Hošek P, Chudáček Z, Ferda J, Hes O, Hora M.

Urol Int. 2017;98(2):148-155. doi: 10.1159/000448434. Epub 2016 Sep 30.

PMID:
27684070
46.

Comparative study of TERT gene mutation analysis on voided liquid-based urine cytology and paraffin-embedded tumorous tissue.

Pivovarcikova K, Pitra T, Vanecek T, Alaghehbandan R, Gomolcakova B, Ondic O, Peckova K, Rotterova P, Hora M, Dusek M, Michal M, Hes O.

Ann Diagn Pathol. 2016 Oct;24:7-10. doi: 10.1016/j.anndiagpath.2016.06.002. Epub 2016 Jun 18. No abstract available.

PMID:
27649946
47.

Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant.

Foix MP, Dunatov A, Martinek P, Mundó EC, Suster S, Sperga M, Lopez JI, Ulamec M, Bulimbasic S, Montiel DP, Alaghehbandan R, Peckova K, Pivovarcikova K, Ondrej D, Rotterova P, Skenderi F, Prochazkova K, Dusek M, Hora M, Michal M, Hes O.

Virchows Arch. 2016 Dec;469(6):669-678. Epub 2016 Sep 15.

PMID:
27631338
48.

Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.

Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, Hes O, Klecka J, Babuska V, Rousarova M, Benson V, Pesta M.

Anticancer Res. 2016 Sep;36(9):4787-93.

PMID:
27630329
49.

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy.

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Volpe A, Bex A.

Eur Urol. 2016 Nov;70(5):705-706. doi: 10.1016/j.eururo.2016.06.009. Epub 2016 Jun 24.

PMID:
27349614
50.

Solid papillary renal cell carcinoma: clinicopathologic, morphologic, and immunohistochemical analysis of 10 cases and review of the literature.

Ulamec M, Skenderi F, Trpkov K, Kruslin B, Vranic S, Bulimbasic S, Trivunic S, Montiel DP, Peckova K, Pivovarcikova K, Ondic O, Daum O, Rotterova P, Dusek M, Hora M, Michal M, Hes O.

Ann Diagn Pathol. 2016 Aug;23:51-7. doi: 10.1016/j.anndiagpath.2016.04.008. Epub 2016 Apr 27. Review. No abstract available.

PMID:
27209513

Supplemental Content

Support Center